ASH: Gilead/Arcellx Point To Anito-Cel’s Safety, High-Risk Patient Advantages

 
• By Alaric DeArment
  
Gilead at ASH 2024 (Alaric DeArment/Scrip)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cell Therapies

More from Conferences